Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. - Wikidata - awgldk - TriplyDB

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

http://www.wikidata.org/entity/Q45001560

about

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.Population pharmacokinetic analysis of sorafenib in patients with solid tumours.UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.Ugt1a is required for the protective effect of selenium against irinotecan-induced toxicity.Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.Clinical pharmacogenetics of irinotecan (CPT-11).Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs.GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.Pharmacogenomics in colorectal cancer: the first step for individualized-therapy Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?PhRMA white paper on ADME pharmacogenomics.Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid.Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity.α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects.Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.Gastrointestinal toxicity of mycophenolate mofetil in rats: Effect of administration time.Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities.Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population.Shengjiang Xiexin Decoction Alters Pharmacokinetics of Irinotecan by Regulating Metabolic Enzymes and Transporters: A Multi-Target Therapy for Alleviating the Gastrointestinal Toxicity.Germline genetic variants with implications for disease risk and therapeutic outcomes.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.Use of genome-wide high-throughput technologies in biomarker development

P2860

Q34565071-2472DBCE-0880-49F3-A193-EAC3D55B4ABA Q35008045-51A3D913-A889-4415-92CA-C2F2AE03C44D Q35183640-3B158384-76EB-4AB1-8B7F-DB34ABDEECF3 Q35688457-7DD110AA-1D3A-4D6B-BAE6-558909361247 Q35857153-33FD235A-D9F2-471C-8515-BBF092EC0911 Q36102590-179610A9-CAE0-4244-AA06-D80FB23CEEBE Q36300812-D50F2F30-B8B9-46E8-B5D7-12ACF70D7785 Q36528861-73E2ADFE-AF15-4E59-86BC-2577B85669F8 Q36551126-15C05119-B10E-4670-A44E-09ACD973905C Q36785973-B316CA0B-FDBC-42B5-B021-F1820B223C77 Q36847276-B13D7774-BCF8-40D5-968D-BF5315EEA6A1 Q36943992-3C928396-98D6-467B-9087-7D933A429D63 Q36996329-E050410C-B3EE-415A-B5BA-F9F313B5F681 Q37092485-DF09082C-ABBE-4D56-AC0D-2B30B0CCBC72 Q37173199-F176C79E-3ADE-4EC4-B9AC-FD44712FDEE7 Q37182212-CC2C961A-0208-44C0-BF6D-D65B24B493AA Q37312970-3D8D477B-0C9F-4B3E-9D4C-CFA83357E2AF Q37345974-E404CCB7-CB87-4811-A298-AB7F888B6BA0 Q37356204-546BA787-DE33-4397-9B28-3B8BA5A74C25 Q37775981-90B34FCD-98B4-453E-B3F2-EA82C136583D Q37834445-FF23BCA2-F588-4ACE-BFCA-1CE93740CB51 Q38030052-FA2FCECC-68FB-4D1E-96CF-FA7AD9AB8D5B Q38107101-CC0F8EBF-2AC4-4C63-A875-D532BBDACC20 Q38831103-B014D05F-7348-4E5B-989C-1495C29C6B89 Q39868674-E8023817-90FB-4D00-9ED2-F156208B7904 Q40337822-49BFE6A8-A2EB-4808-8927-6221308C2E7F Q43125236-94CF5176-A29E-4F63-AB7C-2A26CEA0E28B Q45983432-EF1CC8F5-A632-4A3A-8512-859BBF86EDAF Q47107453-3B7FED55-037A-4304-870D-7E4811672C2C Q48100807-0AFF6284-531B-48DA-8D6C-194C38B93B96 Q52362144-07869DB2-970F-40E9-AB47-6B3D6E4B7608 Q53449568-678B0E7B-DD14-4D03-B674-08FE9234BC11 Q57556407-FFE22CA1-272A-41A6-8E6A-C852B4D9F537

P2860

Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.

http://www.wikidata.org/entity/Q45001560

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Influence of genetic variants ...... vivo glucuronidation of SN-38.

@en

Influence of genetic variants ...... vivo glucuronidation of SN-38.

@nl

type

label

Influence of genetic variants ...... vivo glucuronidation of SN-38.

@en

Influence of genetic variants ...... vivo glucuronidation of SN-38.

@nl

prefLabel

Influence of genetic variants ...... vivo glucuronidation of SN-38.

@en

Influence of genetic variants ...... vivo glucuronidation of SN-38.

@nl

P1433

Q45001560-88864CCC-CFA5-42B3-8A04-FE0070B031A9

P1476

Q45001560-FCDD9D4D-92A1-47CF-8435-2AF240324784

P2093

Q45001560-01560CD6-8441-4022-B781-D187A26470C7

Q45001560-1A1A6F82-00D3-490C-961B-84ED4ADFD8DB

Q45001560-441C1FDD-240D-4B34-8F9C-2B05626CFB7D

Q45001560-7F82E139-1235-4DC5-A752-F14BD771D010

Q45001560-A6CBC8D4-ACEB-4A0D-B355-FE43F061B400

Q45001560-D2398243-D1D0-42DA-B5E5-623151BC220B

P2860

Q45001560-0160F4F6-F151-46FA-85C4-666E15B1517D

Q45001560-03533D1E-5172-4A35-9C62-8B3949EF2C7F

Q45001560-0E0FA444-D9C4-431D-8984-37969767BF60

Q45001560-11E2577F-E97A-4A05-8749-E9FB43075CEC

Q45001560-2EDDD119-54B2-4D99-952A-546804F3072F

Q45001560-364694DB-4CAE-4AE7-B6E0-A80290D2F134

Q45001560-3819963D-4F18-4CE7-9CD1-FAEC0E8EEB8B

Q45001560-3CF1092C-F856-493A-9BDB-FDF6C73E038D

Q45001560-47D38AF7-DBFF-4204-874A-C09B62A49FBF

Q45001560-558303CD-D515-4C32-BF17-8F66994647F0

P304

Q45001560-142CE11E-B6F8-442E-8E25-FD292A131FD2

P31

Q45001560-3C7D08A4-2B6C-4C22-8E28-2752BD44D44E

P356

Q45001560-2EAFDCD9-713B-4780-B06E-279465E693FC

P433

Q45001560-B74D2170-4983-4025-AF4F-E560C807C6C4

P478

Q45001560-3FA253A1-3C8B-450E-A876-3DEE2084FDA7

P50

Q45001560-1ACA0E08-7236-4352-B19E-35F510A3478F

Q45001560-2D848E87-7C31-49D7-B352-8E8563557416

P577

Q45001560-DA697126-BFD1-4B04-9567-45C220D6EBC2

P5875

Q45001560-39B3833C-D762-4B02-B494-CD7E424995BB

P698

Q45001560-A941C636-BD69-407D-B201-966B790BA09F

P356

0091270004267159

P1433

The Journal of Clinical Pharmacology

P1476

Influence of genetic variants ...... vivo glucuronidation of SN-38.

@en

P2093

Arun S Singh

http://www.w3.org/2001/XMLSchema#string

Douglas K Price

http://www.w3.org/2001/XMLSchema#string

Jaap Verweij

http://www.w3.org/2001/XMLSchema#string

Romano Danesi

http://www.w3.org/2001/XMLSchema#string

Ron H J Mathijssen

http://www.w3.org/2001/XMLSchema#string

William D Figg

http://www.w3.org/2001/XMLSchema#string

P2860

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues

Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.

Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene.

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome.

Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation.

Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects.

P304

854-860

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270004267159

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P50

Alex Sparreboom

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8424147

http://www.w3.org/2001/XMLSchema#string

P698

15286088

http://www.w3.org/2001/XMLSchema#string